Compare EARN & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | CATX |
|---|---|---|
| Founded | 2012 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.7M | 211.1M |
| IPO Year | 2013 | N/A |
| Metric | EARN | CATX |
|---|---|---|
| Price | $5.32 | $2.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $5.88 | ★ $11.56 |
| AVG Volume (30 Days) | 323.8K | ★ 1.6M |
| Earning Date | 02-20-2026 | 11-10-2025 |
| Dividend Yield | ★ 18.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,893,000.00 | $1,075,000.00 |
| Revenue This Year | $8.43 | N/A |
| Revenue Next Year | $17.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 43.30 | N/A |
| 52 Week Low | $4.33 | $1.60 |
| 52 Week High | $6.86 | $5.39 |
| Indicator | EARN | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 56.59 |
| Support Level | $5.10 | $2.45 |
| Resistance Level | $5.20 | $2.90 |
| Average True Range (ATR) | 0.10 | 0.21 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 60.18 | 81.18 |
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.